In addition, the company is developing several mid-to-late-stage therapies, including a second complement inhibitor, a copper-binding agent for Wilson disease and an anti-neonatal Fc receptor (FcRn) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback